Sorafenib Inhibits Doxorubicin-Induced PD-L1 Upregulation to Improve Immunosuppressive Microenvironment in Osteosarcoma

Author:

Wang Jizhuang1,Hu Fangqiong1,Yu Pei1,Wang Jun1,Liu Zhuochao1,Bao Qiyuan1,Wen Junxiang1

Affiliation:

1. Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Abstract

Abstract Purpose: Although undergoing conventional chemotherapy significantly improves the prognosis of osteosarcoma, chemoresistance and failure of therapy is still a significant challenge. Furthermore, conventional chemotherapy, like doxorubicin, would upregulate the expression of Programmed death-ligand 1 (PD-L1) which caused an immunosuppressive microenvironment and unsatisfied treatment result in Osteosarcoma. Thus, it is urgent to explore a strategy to overcome this disadvantage.Methods: Human Osteosarcoma cell line MG63 and mouse Osteosarcoma cell line K7 were included in this study. Subcutaneous tumor model was used by injection K7 cells in BALB/C mice to test the effect of doxorubicin and sorafenib on tumor growth. PD-L1 expression was tested in vitro (flow cytometry, western blot and PCR) and in vivo (flow cytometry and immunohistochemistry). Proportion of immune cells (CD4, CD8, Tregs and cytotoxic T lymphocytes) in vivo was analyzed with flow cytometry.Results: Combination of sorafenib and doxorubicin inhibited tumor growth significantly in vivo. Doxorubicin increased PD-L1 expression in vitro and in vivo, while sorafenib inhibited doxorubicin-induced PD-L1 upregulation in vitro and in vivo. Proportion of interferon-γ-secreting CD8+ T lymphocytes in tumor tissue was increased significantly when combined sorafenib with doxorubicin, while proportion of CD4, CD8 and Tregs was not significantly changed. Extracellular Signal-Regulated Kinases (ERK) pathway could be one of the key mechanisms by which doxorubicin induced upregulation of PD-L1 in osteosarcoma cells.Conclusion: Combination of sorafenib and conventional chemotherapeutic reagents is a potent strategy to improve treatment effectiveness by modulating tumor micro environment in Osteosarcoma through increasing proportion of cytotoxic T lymphocytes.

Publisher

Research Square Platform LLC

Reference41 articles.

1. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer;Alizadeh D;Cancer research,2014

2. Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up;Bielack S;Annals of Oncology,2009

3. Bone Cancer Clinical Practice Guidelines in Oncology;Biermann JS;Journal of the National Comprehensive Cancer Network,2013

4. Oncology meets immunology: the cancer-immunity cycle;Chen DS;Immunity,2013

5. RANKL blockade prevents and treats aggressive osteosarcomas;Chen Y;Science translational medicine,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3